SCHEMBL95570

SCHEMBL95570

CCCNCC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11420212 1.00 SAT1 (0.60)
Hydrochloric Acid SCHEMBL6609960 0.97
SCHEMBL17355046 0.95 SAT1 (0.61)
SCHEMBL24540363 0.91 SAT1 (0.52)
SCHEMBL1795740 0.91 SAT1 (0.52)
SCHEMBL5626798 0.90 SAT1 (0.50)
SCHEMBL26507012 0.90
SCHEMBL7877684 0.89 SAT1 (0.73)
Hydrochloric Acid SCHEMBL5379319 0.87 GNAI3 (0.48)
SCHEMBL11922715 0.87 SAT1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 707 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103347866-B As the noval chemical compound of the respiratory stimulant for the treatment of control of breathing discomfort or disease GALLEON PHARMACEUTICALS, INC. (US) 2016-05-18 CN claimed
CN-103347866-A Novel compound as respiratory stimulants for treatment of breathing control disorder or disease GALLEON PHARMACEUTICALS INC 2013-10-09 CN claimed
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2011-11-24 US claimed
EP-1805166-B1 QUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-07-27 EP claimed
EP-2342173-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS Novartis AG (CH) 2011-07-13 EP claimed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US claimed
WO-2010043584-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2010-04-22 WO claimed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US claimed
EP-1569911-B1 INDAZOLE DERIVATIVES AS CRF ANTAGONISTS HOFFMANN LA ROCHE (CH) 2008-07-02 EP claimed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 EP claimed
WO-2004069803-A2 MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES AND THEIR USE AGAINST CANCER F. HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO claimed
US-6627624-B1 Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, NEUROGEN CORPORATION 2003-09-30 US claimed
EP-1019046-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM (US) 2002-11-27 EP claimed
US-20020049316-A1 Protease inhibitors HALBERT STACIE MARIE (US) 2002-04-25 US claimed
EP-1019046-A1 PROTEASE INHIBITORS Smithkline Beecham (US) 2000-07-19 EP claimed
WO-1998048799-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1998-11-05 WO claimed
US-5140022-A Muscle relaxants ANAQUEST, INC. (US) 1992-08-18 US claimed
EP-0478910-A2 3-Substituted-aminomethyl-3-substituted-oxy-17A-methyl-17A-lower-alkyl-17A-aza-d-homo-5-alpha-androstanes Anaquest, Inc. (US) 1992-04-08 EP claimed
US-4275238-A CYCLIZING BUTANEDIOL USING A COBALT CATALYST, ALKYLATING WITH PROPYLAMINE CIBA-GEIGY CORPORATION (US) 1981-06-23 US claimed
US-4264527-A REACTING CYCLOPROPYLMETHYLAMINE WITH PROPIONITRILE IN THE PRESENCE OF A HYDROGENATION CATALYST AND HYDROGEN CIBA-GEIGY CORPORATION (US) 1981-04-28 US claimed